Roche Posts Positive Phase 3 Interim Results in Hemophilia Study
December 07 2017 - 2:33AM
Dow Jones News
By Euan Conley
Roche Holding AG (ROG.EB) on Thursday said that its phase 3
study of hemophilia A treatment Hemlibra has yielded positive
interim results, which may ultimately give patients greater freedom
when choosing treatment options.
As part of the Haven 4 study, adults and adolescents aged 12 or
older who suffer from the blood disease received a dose of the
prophylaxis once every four weeks. Its findings show "clinically
meaningful" control of bleeding after a median of 17 weeks of
treatment, Roche said.
The company said that the results are consistent with previous
studies of Hemlibra that set the dosage at once a week or once
every fortnight. Some treatments for hemophilia A require sufferers
to undergo frequent intravenous infusions.
"Together with the findings from other phase 3 studies, these
interim results support the potential for Hemlibra to be dosed at
different schedules, allowing patients to choose the option that's
right for them," said Sandra Horning, Roche's chief medical officer
and head of global product development.
Write to Euan Conley at euan.conley@dowjones.com
(END) Dow Jones Newswires
December 07, 2017 02:18 ET (07:18 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Sep 2024 to Oct 2024
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Oct 2023 to Oct 2024